» Articles » PMID: 37932121

Therapeutic Phage Monitoring: A Review

Overview
Journal Clin Infect Dis
Date 2023 Nov 6
PMID 37932121
Authors
Affiliations
Soon will be listed here.
Abstract

With the global rise in antimicrobial resistance, there has been a renewed interest in the application of therapeutic phages to treat bacterial infections. Therapeutic phage monitoring (TPM) is proposed as an essential element of phage therapy (PT) protocols to generate data and fill knowledge gaps regarding the in vivo efficacy of therapeutic phages, patients' immune responses to PT, and the wider ecological effects of PT. By monitoring phage concentrations in blood and tissues, together with immune responses and possible ecological changes during PT, TPM may enable the optimization of dosing and the implementation of precision medicine approaches. Furthermore, TPM can validate diagnostic surrogates of efficacy, direct research efforts, and establish quality assurance indicators for therapeutic phage products. Thus, TPM holds great potential for enhancing our understanding of the multidirectional phage-bacteria-host interactions and advancing "best practice" PT, ultimately improving patient care.

Citing Articles

Bacteriophage therapy for multidrug-resistant infections: current technologies and therapeutic approaches.

Kim M, Suh G, Cullen G, Perez Rodriguez S, Dharmaraj T, Chang T J Clin Invest. 2025; 135(5).

PMID: 40026251 PMC: 11870740. DOI: 10.1172/JCI187996.


New materials and complications of prostheses in humans: situation in Spain.

Vallet-Regi M, De Alarcon A, Gomez Barrena E, Planell J, Silva J, Bouza E Rev Esp Quimioter. 2024; 37(5):369-386.

PMID: 38779807 PMC: 11462316. DOI: 10.37201/req/039.2024.


Efficacy and clinical potential of phage therapy in treating methicillin-resistant Staphylococcus aureus (MRSA) infections: A review.

Fortaleza J, Ong C, De Jesus R Eur J Microbiol Immunol (Bp). 2024; 14(1):13-25.

PMID: 38305804 PMC: 10895361. DOI: 10.1556/1886.2023.00064.